Shore Capital Group reiterated their hold rating on shares of Diploma (LON:DPLM – Free Report) in a research note released on Wednesday morning, Marketbeat.com reports.
DPLM has been the topic of a number of other research reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 6,350 price target on shares of Diploma in a research report on Wednesday, November 19th. Peel Hunt reiterated a “buy” rating and issued a GBX 6,150 price objective on shares of Diploma in a research report on Friday, December 19th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Diploma from GBX 6,000 to GBX 6,200 and gave the stock a “buy” rating in a research note on Wednesday, January 14th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 5,634.29.
Read Our Latest Stock Report on DPLM
Diploma Stock Performance
Insider Buying and Selling
In related news, insider Ian El-Mokadem purchased 500 shares of Diploma stock in a transaction that occurred on Wednesday, January 14th. The stock was purchased at an average cost of GBX 5,615 per share, with a total value of £28,075. Also, insider Wilson Ng purchased 410 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was bought at an average price of GBX 5,369 per share, with a total value of £22,012.90. Insiders acquired a total of 1,262 shares of company stock worth $6,995,830 in the last three months. Insiders own 1.14% of the company’s stock.
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
